News
When executed with precision and transparency, ECAs can enhance trial efficiency, expand access and support evidence—while ...
Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback